Vol. XXIX, n.5, 2008 ISSN: 0392-2936


european journal
of gynaecological oncology

an International Journal


Founding Editor
A. Onnis
Montréal (Canada)

Editors-in-Chief
M. Marchetti
Montréal (Canada)
P. Bösze
Budapest (Hungary)

Associate Editor
T. Maggino
Padua (Italy)

Assistant Editor
J. Wilson
San Diego - CA (USA)
Editorial Board
Allen H.H., London, Ontario (Canada)
Anteby S.O., Jerusalem (Israel)
Audet-Lapointe P., Montreal (Canada)
Ayhan A., Ankara (Turkey)
Balat O., Graziantep (Turkey)
Ba˘nceanu G., Bucarest (Romania)
Basta A., Krakow (Poland)
Bender H.C., Dusseldorf (Germany)
Benedetti Panici P.L., Rome (Italy)
Charkviani T., Tbilisi (Georgia)
De Oliveira C.F., Coimbra (Portugal)
Dexeus S. Jr., Barcelona (Spain)
Di Paola G.R.,
Buenos Aires (Argentina)
Di Re F., Milan (Italy)
Di Saia P., Orange, CA (USA)
Friedrich M., Hamburg (Germany)
Fuller A.F. Jr., Boston, MA (USA)
Geisler H.E., Indianapolis, IN (USA)
Gerbaulet A., Villejuif (France)
Gorins A., Paris (France)
Heintz A.P.M.,
Utrecht (The Netherlands)
Ioannidou-Mouzaka L.,
Athens (Greece)
Jordan J.A.,
Birmingham, England (UK)
Karseladze A.I., Moscow (Russia)
Klastersky J., Bruxelles (Belgium)
Kubista E., Vienna (Austria)
Maggino T., Padua (Italy)
Markowska J., Poznan (Poland)
Marth C., Innsbruck (Austria)
Massuger Leon F.A.G.,
Nijmegen (The Netherlands)
Menczer J., Savyon (Israel)
Monsonego J., Paris (France)
Pálfalvi L., Budapest, (Hungary)
Pinotti A., São Paulo (Brazil)
Piura B., Beer Sheva (Israel)
Piver S.M., Buffalo, NY (USA)
Rakar S., Ljubljana (Slovenia)
Raju K.S., London, England (UK)
Shepherd J.H.,
London, England (UK)
Stelmachów J., Warsaw (Poland)
Tjalma W., Antwerpen (Belgium)
Ungár L., Budapest (Hungary)
Vermorken J.B., Edegem (Belgium)
Wang P.-H., Taipei (Taiwan)
Winter R., Graz (Austria)
Yokoyama Y., Hirosaki (Japan)

Publishing Organization (M. Morsani):
I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroup-online.com - www.irog.net

Editorial Office (M. Critelli):
Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 - Fax (39) 049 8752018

 

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

 

European Journal of Gynaecological Oncology
www.irog.net


General Information

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynaecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE,
EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

AIMS AND SCOPE
The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distin-guished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the dif-fusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

ANNOUNCEMENTS regarding meetings, postgraduate courses and symposia will be accepted 6 months before publication and will be published free of charge.
BOOK SAMPLES for review should be sent to the Editorial offices in Montréal or in Padova.
COPYRIGHT: the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.
ADVERTISING INFORMATION: advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2HS, Tél. 514.4893242-4893640 - Fax 514.4854513 - E-mail: canlux@mgroup-online.com - www.irog.net
RESPONSIBILITY: although every effort is made by the editorial staff and the printer to eliminate misleading or inaccurate infor-mation, the publisher accepts no responsibility for the consequences of faultful or incorrect information. The authors recognize that the editor and publisher have no responsibility and are indemnified against any liability or claim that may result from the publication of misleading or incorrect data.


SUBSCRIPTION INFORMATION
The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

Subscriptions are entered with prepayment only. The annual subscription is $390 US for Institutions, $200 US for Individuals. For airmail add $30, for receipt add $10 US. Single copy prepaid cost $95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner’s - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. Only US Funds are accepted. No bank transfers.

Claims for missing issues can be honoured up to six months. Changes of address: allow six weeks for all changes to become effec-tive. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and any communication and requests should be addressed to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT

 

European Journal of Gynaecological Oncology
www.irog.net


Instructions to Authors

SUBMISSION OF MANUSCRIPTS
Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Sto-rione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the “Distinguished Expert Series” should be submitted to P. Bösze, Editor-in-Chief of this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest, Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1)
275 2172, E-mail: bosze@axelero.hu

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers’ suggestions.

Manuscripts accepted for publication will be copyedited by the editorial staff for typographical and grammatical mistakes and to guarantee clarity and conciseness.

Publication time will be the shortest possible based on scientific and publishing needs. Manuscripts submitted for publi-cation cannot be returned.

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

After six months no grievances will be accepted regarding published articles.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author’s experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and appli-cation thereof contained in the Journal. Consult the prescribing information before administering any drug.

MANUSCRIPT REQUIREMENTS
The Journal follows the “Uniform requirements for manuscripts submitted to biomedical journals” published in the New England Journal of Medicine 1991, 324, 424-8 and in the British Medical Journal 1991, 302.

Three manuscripts, typed and double spaced should be submitted with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0. Manuscripts without an electronic disk will not be accepted. A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which has never been pub lished or submitted for publication elsewhere. Without a cover letter the publication will not be possible. Name, address and phone/fax numbers of the Corresponding Author, responsible for revision and approval of the proofs, should be indicated. Full-length articles should not exceed 8 printed pages including tables and references.

After the title page (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: Summary (purpose of investiga-tion, methods, results, conclusion - about 150 words), Key words, Content (a 20-word summary), Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement (if any), References, Tables, Legends.

Authors should supply a complete address for reprint requests.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

Authors must give their complete professional identifications and affiliations, including all academic titles and positions.

Letters to the editor should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

Figures: Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author’s name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).

Legends should be typed on a separate page with Arabic numerals corresponding to the illustrations.

Tables should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first cita-tion
in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in Index Medicus. The titles of journals should be abbreviated according to the style used in Index Medicus.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

Articles in Journals: Authors’ surname and initials (if more than six names, give six followed by “et al.”), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue and first page.

Books: Authors’ surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Page.

Acknowledgments
will be limited to appropriate professionals who were contributors to the paper.

PROOFS revised by the editorial staff will be sent to the corresponding author and should be checked and returned within ten days. The corresponding author is responsible for detecting typesetting errors. After this deadline the proofs will be considered approved. Only essential corrections should be made; extensive changes will be charged to the authors.

BUSINESS MATTERS
The Journal has no commercial advertisements.

Authors will be expected to contribute to the printing expenses, tables, figures and postage. For every published article a copy of the Journal will be provided free of charge. Only payments in US dollars will be accepted. No bank transfers.

Reprints should be requested with the form enclosed with the acceptance letter. No free reprints will be supplied.



© By I.R.O.G. CANADA INC. - Publisher - Editorial office 4900 Côte St. Luc - Apt. 212 - Montréal Québec H3W 2H3 (Canada) - Tel. (514) 4893242-4893640 - Fax (514) 4854513 - Printed in Italy by “La Garangola” - Via E. Dalla Costa, 6 - 35129 Padua (Italy) - Responsible Director: Prof. Antonio Onnis M.D. - Authorization of Padua’s Court n. 633 - 28-6-1979
   
European Journal of Gynaecological Oncology - Vol. XXIX, n. 5, 2008
 
   
CONTENTS  
DISTINGUISHED EXPERT SERIES  
Progress in epithelial ovarian carcinoma. Has the outcome been improved? 421
J. Menczer - Holon, ISRAEL
Treatment outcome in epithelial ovarian carcinoma is considered.
 
 
REVIEW ARTICLE  
Preservation of fertility in reproductive-age women with the diagnosis of cancer 425
P. Kovács, S. Mátyás, L. Ungár - Budapest, HUNGARY
With more conservative medical/surgical cancer therapy and improved ART, fertility can often be maintained in young women with cancer.
 
 
ORIGINAL ARTICLES  
Accuracy of frozen section diagnosis at surgery in premalignant and malignant lesions of the endometrium 435
S. Attard Montalto, M. Coutts, O. Devaja, J. Summers, R. Jyothirmayi, A. Papadopoulos - Maidstone Kent, U.K.
A paper reviewing the accuracy of intraoperative assessment of uteri with a preoperative diagnosis of atypical hyperplasia or malignancy.
 
p16 expression in Paget’s disease of the breast 441
F. Buxant, J.C. Noël - Brussels, BELGIUM
p16 overexpression in Paget’s disease could explain the spread of the disease.
 
Immunohistochemical expression of MMP-2, MMP-9 and COX-2 in Stage IA malignant polyps of the endometrium 444
E. Erdemoglu, M. Güney, N. Karahan, T. Mungan - Isparta, TURKEY
Endometrial cancer associated with polyps may be immunohistochemically more indolent than endometrial cancer not associated with polyps.
 
Expression of the epidermal growth factor system in endometrial cancer 450
G. Adonakis, G. Androutsopoulos, D. Koumoundourou, A. Liava, P. Ravazoula, G. Kourounis - Rion, GREECE
The cerbB-1 has the ability to predict patient survival in endometrial cancer cases.
 
Vulval cancer: what is an adequate surgical margin? 455
J. Balega, J. Butler, A. Jeyarajah, D. Oram, J. Shepherd, A. Faruqi, N. Singh, K. Reynolds - London, U.K.
Naked eye assessment of surgical margins in vulval cancer is inaccurate if aiming at a 1 cm tumour-free margin.
 
Bcl-2 oncogene expression in estrogen receptor-positive and negative breast carcinoma 459
L.G. dos Santos, P.V. Lopes-Costa, A.R. dos Santos, G. Facina, B.B. da Silva - São Paulo, BRAZIL
Bcl-2 oncogene expression was statistically greater in ER+ tumors compared to ER- tumors.
 
CT colonography to detect rectosigmoid involvement in patients with primary ovarian cancer 462
K. Kato, H. Funatsu, K. Suzuka, T. Osaki, A. Imamura, H. Takano, N. Tanaka - Chiba, JAPAN
CT colonography is useful for detecting rectosigmoid involvement in patients with primary ovarian cancer.
 
Gonadotropins and female sex steroid hormones in cyst fluid and serum from patients with ovarian tumors 468
C.M.G. Thomas, E.A. Boss, H. Boonstra, D. van Tienoven, C.G.J. Sweep, L.F.A.G. Massuger - Nijmegen, THE NETHERLANDS
The concentration of gonadotropins and sex steroid hormones in ovarian cyst fluid and serum in patients with benign and malignant ovarian tumors was studied.
 
Platin sensitivity and long-term survival in Stage III epithelial ovarian cancer patients 473
J. Menczer, A. Golan, T. Levy - Tel Aviv, ISRAEL
The rate of platin-sensitive patients was significantly higher among long-term survivors than among short-term survivors but its practical clinical use is limited.
 
Evaluation of prognostic significance in extracapsular spread of pelvic lymph node metastasis in patients with cervical cancer 476
J. Metindir, G. Bilir Dilek - Ankara, TURKEY
This study was performed to clarify the prognostic significance of extracapsular spread of pelvic lymph node metastasis in patients with cervical cancer.
 
Excessive pap smears due to opportunistic cervical cancer screening 479
R.A.P. Freitas, G.A.F. Carvasan, S.S. Morais, L.C. Zeferino - São Paulo, BRAZIL
The screening coverage could have reached 65.4% working as an organized program instead of 14.76 as an opportunistic program.
 
Prognostic factors and adjuvant therapy in uterine carcinosarcoma 483
T.I. Wu, K.H. Hsu, H.J. Huang, S. Hsueh, H.H. Chou, C.S. Tsai, K.C. Ho, A. Chao, T.C. Chang, C.H. Lai - Taoyuan, TAIWAN
Prognostic variables and impact of adjuvant therapy in uterine carcinosarcoma are examined.
 
Staining characterization by immunohistochemistry of tumor cancer antigen in patients with endometrial cancer 489
J. Metindir, G.B. Dilek, I. Pak - Ankara, TURKEY
The correlation between pattern of CA-125 expression and pathologic parameters in endometrial carcinoma was evaluated.
 
Comorbidity and age affect treatment policy for cervical cancer: a population-based study in the south of the Netherlands, 1995-2004 493
M.A. van der Aa, S. Siesling, R.F.P.M. Kruitwagen, M.L.M. Lybeert, J.W.W. Coebergh, M.L.G. Janssen- Heijnen - Rotterdam, THE NETHERLANDS
Influence of age and comorbidity on treatment and prognosis of cervical cancer patients.
 
Prognostic markers of low-grade squamous intraepithelial lesions: the role of topoisomerase IIα and active caspase-3 499
R.A. Coelho, G.R.A. Focchi, N.C. Nogueira-de-Souza, M.G.F. Sartori, I.D.C.G. Silva, J.C.L. Ribalta - São Paulo, BRAZIL
The role of topoisomerase IIα and active caspase-3 as prognostic markers in low-grade squamous intraepithelial lesions were studied.
 
Extraovarian peritoneal serous papillary carcinoma mimicking colonic obstruction 502
T. Theodosopoulos, A. Marinis, A. Yiallourou, N. Dafnios, A. Kondi-Pafiti, I. Vassiliou, V. Smyrniotis, K. Karapanos - Athens, Greece
Five cases with Stage IV extraovarian peritoneal serous papillary carcinoma involving the colon and presenting as large bowel obstruction were revieved.
 
Postoperative radiotherapy in intermediate and high-risk Stage I endometrial cancer: analysis of prognostic factors and survival 505
Y. Bolukbasi, S. Demirci, Z. Ozsaran, D. Yalman, M. Hanhan, A. Ozsaran, Y. Dikmen, A. Aras - Izmir, TURKEY
Stage IA grade G 3, Stage IB G2-3 and Stage IC G1-2-3 endometrial cancer patients treated with postoperative adjuvant radiotherapy were evaluated in relation to local control, disease-free and overall survival rates and prognostic factors.
 
Lysophosphatidic acid: an ovarian cancer marker 511
I. Sedláková, J. Vávrová, J. Tosˇner, L. Hanousek - Hradec Králové, CZECH REPUBLIC
Plasma lysophosphatidic acid (LPA) levels can act as a biomarker for ovarian cancer, particularly in early carcinoma stages.
 
 
CASE REPORTS  
Simultaneous diagnosis and treatment of bilateral breast carcinoma and endometrial adenocarcinoma. Implications for screening 515
I. Dedes, V. Ziogas - Zurich, SWITZERLAND
A unique case regarding simultaneous diagnosis and treatment of bilateral breast carcinoma and endometrial adenocarcinoma is described, and the clinical aspects and treatment of this unique case are presented.
 
A case of extremely chemoresistant pure pleomorphic rhabdomyosarcoma of the uterus associated with a high serum LDH level 518
S. Yeasmin, K. Nakayama, A. Oride, M. Ishibashi, N. Ishikawa, A. Katagiri, K. Iida, N. Nakayama, K. Miyazaki - Izumo, JAPAN
A case of pure pleomorphic uterine rhabdomyosarcoma associated with high serum LDH level that was very chemoresistant is presented.
 
Metastatic spread of gynaecological neoplasms to the adrenal gland: case reports with a review of the literature 523
M. Baron, L. Hamou, S. Laberge, F. Callonnec, A. Tielmans, P. Dessogne - Rouen, FRANCE
Four cases of metastases to the adrenal gland from gynaecological neoplasms are presented and together with a review of the
literature.
 
Primary squamous cell carcinoma of the endometrium: a case report 282
N.E. Tchabo, P. Mhawech-Fauceglia, S. Lele - Buffalo, NY (USA)
This study reports the clinicopathological features of a recent case of PSCCE and discusses the current literature.
 
Primary vaginal melanoma: a case report and literature review 285
M. Schmidt, A. Honig, M. Schwab, P. Adam, J. Dietl - Wuerzburg, GERMANY
Vaginal melanoma is a rare malignancy. Among different treatment options only wide local excision is associated with prolonged survival.
 
Malignant mixed müllerian tumor of primary mesenteric origin associated with a synchronous ovarian cancer: case report and literature review 289
C.J. Ma, S.F. Yang, C.C. Huang, C.Y. Chai, K.I. Cheng, E.M. Tsai, J.Y. Wang - Kaohsiung, TAIWAN
Extragenital MMMTs are rare and may be associated with synchronous gastrointestinal or gynecological malignancies.
 
Pelvic actinomycosis mimicking ovarian malignancy: three cases 294
S.E. Akhan,Y. Dogan, S. Akhan, A.C. Iyibozkurt, S. Topuz, O. Yalcin - Istanbul, TURKEY
Three cases of pelvic actinomycosis mimicking ovarian cancer are described. All cases had a history of IUD use.
 
A case of endometrial carcinoma arising in a 36-year-old woman with uterine atypical polypoid adenomyoma (APA) 298
K. Bakalianou, N. Salakos, C. Iavazzo, G. Paltoglou, K. Papadias, A. Kondi-Pafiti - Athens, GREECE
A case of endometrial carcinoma arising in a 36-year-old woman with atypical polypoid adenomyoma is presented.
 
Immature teratoma in pregnancy: a case report and literature review 300
A. Daponte, E. Kostopoulou, A. Zavos, H. Skentou, A. Kallitsaris, G. Koukoulis, I.E. Messinis - Larissa, GREECE
An immature Stage I teratoma was removed during pregnancy. Appropriate surgical staging enabled avoidance of chemotherapy despite the unexpected histological diagnosis.